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Abstract
Background: Rituximab is a monoclonal antibody inducing depletion of B lymphocytes and presently approved for 
the treatment of non-Hodgkin's lymphoma and rheumatoid arthritis. Here is the first report of the use of this drug in a 
case of Cogan's syndrome (CS).
Case Presentation: a 25-year-old Italian woman was referred with conjunctival hyperaemia, interstitial keratitis, 
moderate bilateral sensorineural hearing loss accompanied by tinnitus, dizziness, nausea and vertigo, poorly 
responsive to oral and topical steroidal therapy. Diagnosis of typical CS was made. The administration of a combined 
immunosuppressive treatment resolved ocular inflammation, dizziness, nausea, and vertigo but gave little results in 
controlling progressive hearing loss. A noticeable improvement in hearing function was documented by pure tone 
audiometry after infusion of Rituximab.
Discussion: in CS, hearing function is often the most difficult parameter to control with therapy. A positive effect of 
Rituximab on was observed in our case. The drug also allowed to significantly reduce the number of adjuvant 
immunosuppressive medications.
Background
Rituximab is a chimeric human-mouse monoclonal anti-
body against lymphocyte CD20 surface antigen, and
treatment induces depletion of B lymphocytes by various
mechanisms. These antibodies are thought to act in vivo
mostly through activation of antibody-dependent cell-
mediated cytotoxicity and complement-dependent cyto-
toxicity, although direct growth inhibition and/or induc-
tion of apoptosis may also take place [1]. Rituximab is
presently approved for the treatment of non-Hodgkin's
lymphoma and rheumatoid arthritis. Here is the first
report of the use of this drug in a case of severe Cogan's
syndrome (CS).
Case Presentation
A 25-year-old Italian woman developed severe bilateral
sensorineural hearing loss over the course of 12 months
from her first acute inflammatory episode characterized
by conjunctival hyperaemia, interstitial keratitis and tin-
nitus. Before the admission, the patient had already expe-
rienced a 3-week regimen of oral prednisone (50 mg/day
at regressive dosage) and dexametasone eye-drops with
poor response. After the patient had been screened for a
possible infectious origin of her symptoms and all other
known causes of interstitial keratitis had been excluded
(i.e. syphilis, sarcoidosis, leprosy, Lyme disease, viruses,
hypersensitivity to drugs), diagnosis of typical CS was
confirmed by positive anti-hsp 70 antibody[2]. An immu-
nosuppressive combination therapy was thus started fol-
lowing the reference protocol of our Centres for systemic
autoimmune diseases[3]. It consisted of pulse intravenous
cyclophosphamide (400 mg IV once a month, for 6 con-
secutive months), intramuscular methotrexate (10 mg/
sqm once a week with folic acid integration), oral
cyclosporine (2.5 mg/kg of lean body weight per day) and
prednisone (40 mg per week). Treatment controlled the
relapsing ocular inflammation and stopped progression
of the typical, ring-shape interstitial keratitis. It was also
successful in achieving good control of accompanying
s y m p t o m s  s u c h  a s  d i z z i n e s s ,  n a u s e a ,  a n d  v e r t i g o .  T h e
same treatment, however, gave poor results in controlling
progressive hearing loss (figure 1). An anti-Tumour
Necrosis Factor (anti-TNF) molecule (adalimumab, 40
mg once a week subcutaneously) was then associated to
prednisone and methotrexate for 6 months, but hearing
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loss continued to worsen. Following the patient's
informed consent and approval of local ethics committee,
Rituximab was infused as an "off label" adjuvant rescue
treatment at the dosage of 500 mg iv/week for 4 consecu-
tive weeks. The same regimen was repeated after 6
months, while oral prednisone at 10 mg every other day
was maintained. A noticeable improvement in hearing
function was documented by pure tone audiometry start-
ing from the 28th day after the first drug infusion, mostly
affecting the right ear (figure 2). The pre-treatment
CD19+ lymphocyte count was 73 cells/uL, which then
decreased below the detectibly threshold after the infu-
sion cycles. No other undesirable effects were recorded
during or after therapy. At 12 months of follow-up, the
audiometry curve was still better than pre-treatment lev-
els and essentially unchanged in comparison to that
shown in figure 2. Other previously experienced manifes-
tations of the syndrome remained under control.
Conclusions
Cogan's Syndrome is a rare autoimmune vasculitis char-
acterized by bilateral interstitial keratitis associated with
vertigo, tinnitus and typically profound sensorineural
deafness. This clinical presentation is called "typical" CS.
"Atypical" CS is the name given to those forms with simi-
lar vestibuloauditory symptoms but ocular involvement
different from interstitial keratitis (i.e. scleritis, retinal
vasculitis, papillitis, etc), and/or other severe systemic
Figure 1 The symbols "" for the right ear and "x" for the left ear indicate the auditory threshold for a stimulus transmitted through the air 
of a frequency ranging from 125 to 800 MHz. The symbols ">" for the right ear and "<" for the left ear represent the auditory threshold for a stimulus 
transmitted through the bone of a frequency ranging from 250 to 4000 MHz. The presented audiogram allows the calculation of the Pure Tone Aver-
age (PTA) for the central frequencies which quantifies the average auditory deficit as 61 dB for the right ear and 62 dB for the left ear. At the bottom 
of the figure the auditory thresholds of the stapedial reflex are shown.Orsoni et al. Orphanet Journal of Rare Diseases 2010, 5:18
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vasculitic manifestation[4,5]. Considering both forms, CS
is a rare clinical entity which usually occurs in early adult-
hood but with possible onset in children or in elderly
patients [6,7]. Anti hsp-70 antibody has been indicated as
a marker of the autoimmune origin of hearing loss [2].
While different immunomodulatory drugs, including
mycophenolate and anti-TNF molecules, have been pro-
posed in CS with satisfactory results, refractory cases are
still reported, most concerning hearing function [7-10].
The use of Rituximab in systemic vasculitis and autoim-
mune diseases with antibody-mediated aetiology has a
strong rationale and is increasingly reported in the litera-
ture [11,12]. In CS, hearing function seems to be the most
difficult parameter to control with therapy. The effect of
Rituximab on B cells may therefore be of interest to avoid
deafness and the demand of cochlear implant in severe
cases. It can also allow to significantly reduce the number
of medications necessary to control the multiple manifes-
tations of the syndrome. We recommend the four-week
division of the overall cycle dose of the drug as it appears
to be particularly safe, even though we do not recom-
mend the use of this drug as a first line therapy.
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Figure 2 The audiogram allows the calculation of the Pure Tone 
Average (PTA) for the central frequencies which quantifies the 
average auditory deficit as 45 dB (16 dB of improvement) for the 
right ear and 57 dB for the left ear.